Trial Profile
A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Brain metastases
- Focus Adverse reactions; Pharmacokinetics
- 01 May 2022 Status changed from active, no longer recruiting to discontinued as per results published in the Radiotherapy and Oncology
- 01 May 2022 Results published in the Radiotherapy and Oncology
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.